Technical Analysis for SLRN - Acelyrin Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 200 DMA Resistance | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -1.06% | |
| Fell Below 200 DMA | Bearish | -1.06% | |
| MACD Bearish Signal Line Cross | Bearish | -1.06% | |
| Hammer Candlestick | Bullish | -1.06% | |
| Wide Bands | Range Expansion | -1.06% | |
| Gapped Down | Weakness | -1.06% |
| Alert | Time |
|---|---|
| Down 2 % | about 19 hours ago |
| Hammer Candlestick Entry | about 23 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| Up 2% | about 23 hours ago |
| Rose Above 20 DMA | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/08/2024
Acelyrin Inc. Description
ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.605 |
| 52 Week Low | 3.36 |
| Average Volume | 742,215 |
| 200-Day Moving Average | 5.69 |
| 50-Day Moving Average | 5.21 |
| 20-Day Moving Average | 5.77 |
| 10-Day Moving Average | 6.05 |
| Average True Range | 0.38 |
| RSI (14) | 49.24 |
| ADX | 23.32 |
| +DI | 20.79 |
| -DI | 23.30 |
| Chandelier Exit (Long, 3 ATRs) | 5.38 |
| Chandelier Exit (Short, 3 ATRs) | 5.62 |
| Upper Bollinger Bands | 6.87 |
| Lower Bollinger Band | 4.67 |
| Percent B (%b) | 0.43 |
| BandWidth | 38.17 |
| MACD Line | 0.22 |
| MACD Signal Line | 0.29 |
| MACD Histogram | -0.065 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.04 | ||||
| Resistance 3 (R3) | 6.06 | 5.95 | 5.97 | ||
| Resistance 2 (R2) | 5.95 | 5.84 | 5.94 | 5.95 | |
| Resistance 1 (R1) | 5.78 | 5.77 | 5.73 | 5.76 | 5.92 |
| Pivot Point | 5.67 | 5.67 | 5.64 | 5.66 | 5.67 |
| Support 1 (S1) | 5.50 | 5.56 | 5.45 | 5.48 | 5.32 |
| Support 2 (S2) | 5.39 | 5.49 | 5.38 | 5.29 | |
| Support 3 (S3) | 5.22 | 5.39 | 5.27 | ||
| Support 4 (S4) | 5.20 |
